It is highly unlikely they would be able to continue with the treatment. The first in human phase 2 trials are generally small-scaled with primary endpoints to establish safety, pharmacokinetics (how the drug moves in the body such as distribution, absorption, metabolism, excretion etc) and pharmacodynamics (how the drug acts on the body such as receptor binding (inhibiting, activating etc)). Efficacy is generally only the second endpoint for Phase 2 and is to be further investigated in large-scale Phase 3 trials. Treatment continuation is often following ph3 trials to obtain more data and especially if the drug is working for serious or terminal conditions with no other treatment options (unethical to withhold lifesaving/changing drugs).
Share Price, page-7185
-
- There are more pages in this discussion • 3,663 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.583B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $3.990M | 196.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 16 | $20.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 129 | 5 |
View Market Depth
| Last trade - 13.39pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |